Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Comparative Long-Term Outcomes of Vedolizumab and TNF Inhibitors in Patients with Ulcerative Colitis

  • By

  • Siddharth Singh

  • Jonas Söderling

  • Anders Forss

  • Mathias Rask-Andersen

  • Jonas Halfvarson

  • Åsa H. Everhov

  • Jonas F. Ludvigsson

  • Ola Olén

  • SWIBREG study group

  • Malin Olsson

  • Pär Myrelid

  • Henrik Hjortswang

  • Jonas Bengtsson

  • Hans Strid

  • Marie Andersson

  • Susanna Jäghult

  • Caroline Nordenvall

  • Charlotte Hedin

  • Martin Rejler

  • Olof Grip

  • Ulrika L Fagerberg

  • Karl Mårild

  • Johann Hreinsson

  • Pontus Karling

  • September 25, 2026

Share

  • 1

    The study compares long-term outcomes of infliximab, adalimumab, and vedolizumab in biologic-naive patients with ulcerative colitis.

  • 2

    Data was collected from Swedish population-based registers, ensuring comprehensive follow-up and capturing long-term treatment outcomes.

  • 3

    Primary outcomes included all-cause hospitalization rates, while secondary outcomes focused on IBD-related hospitalizations and corticosteroid use.

  • 4

    Patients were classified by their initial treatment choice, regardless of subsequent therapy changes or clinical events during follow-up.

  • 5

    The study adhered to ethical guidelines, with informed consent waived for register-based research under Swedish law.

Original Source(s)

Vedolizumab vs TNF Antagonists and Long-Term Outcomes in Ulcerative Colitis

  • by Siddharth Singh, Jonas Söderling, Anders Forss, Mathias Rask-Andersen, Jonas Halfvarson, Åsa H. Everhov, Jonas F. Ludvigsson, Ola Olén, SWIBREG study group, Malin Olsson, Pär Myrelid, Henrik Hjortswang, Jonas Bengtsson, Hans Strid, Marie Andersson, Susanna Jäghult, Caroline Nordenvall, Charlotte Hedin, Martin Rejler, Olof Grip, Ulrika L Fagerberg, Karl Mårild, Johann Hreinsson, Pontus Karling

  • September 25, 2026

Related Content

Retraction Note: TWIST1 activates cancer stem cell marker genes to promote epithelial‑mesenchymal transition and tumorigenesis in esophageal squamous cell carcinoma

Long-term outcomes in recurrent diverticulitis: a systematic review of treatment strategies and recurrence rates

Racial disparities in the rate of same-admission cholecystectomy following biliary pancreatitis